Network meta-analysis
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); background therapy: one or more non insulin glucose lowering drugs
weeks 36 to 64 (target week 52)Not stated by the trialsEach dose separatelyMean difference
17
Randomized trials
30
Treatments
10,534
Participants
52
Trial arms
In plain language
Across 17 trials with 10,534 participants, 8 of 29 treatments had a clearly better result than placebo on body weight change in kilograms (diabetes), 2 a clearly worse one, and for 19 the evidence could not tell them apart from placebo. The most favorable estimate was for Tirzepatide 15 mg subcutaneous once weekly: mean difference -11.38 kg (95% credible interval -14.21 to -7.82).
Lower values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Effects compared with Placebo
Mean difference in kg. Lower values favor the treatment.
| Treatment | Bayesian MD (95% CrI) | 95% prediction interval | Frequentist MD (95% CI) | Verdict |
|---|---|---|---|---|
| Tirzepatide 15 mg subcutaneous once weekly TIRZ_SC_15MG_QW | -11.38 (-14.21 to -7.82) | -14.62 to -7.41 | -12.00 (-15.00 to -9.00) | Better |
| Semaglutide 16 mg injection once weekly SEMA_SC_16MG_QW | -10.60 (-13.47 to -7.54) | -13.91 to -7.23 | -10.80 (-13.64 to -7.96) | Better |
| Tirzepatide 10 mg subcutaneous once weekly TIRZ_SC_10MG_QW | -9.00 (-11.73 to -5.35) | -12.13 to -4.91 | -9.61 (-12.61 to -6.60) | Better |
| Semaglutide 8 mg injection once weekly SEMA_SC_8MG_QW | -7.61 (-10.38 to -4.92) | -10.77 to -4.46 | -7.80 (-10.43 to -5.17) | Better |
| Semaglutide 2.0 mg subcutaneous once weekly SEMA_SC_2p0MG_QW | -6.41 (-9.36 to -3.49) | -9.72 to -3.16 | -6.60 (-9.45 to -3.75) | Better |
| Tirzepatide 5 mg subcutaneous once weekly TIRZ_SC_5MG_QW | -6.14 (-8.83 to -2.42) | -9.23 to -1.90 | -6.68 (-9.69 to -3.68) | Better |
| Semaglutide 1.0 mg subcutaneous once weekly SEMA_SC_1p0MG_QW | -3.86 (-5.92 to -1.33) | -6.35 to -0.80 | -4.29 (-6.54 to -2.04) | Better |
| Cotadutide 300 ug subcutaneous once daily COTA_SC_300UG_QD | -3.06 (-4.84 to -0.98) | -5.36 to -0.32 | -3.22 (-4.90 to -1.54) | Better |
| Canagliflozin CANAGLIFLOZIN | -2.46 (-5.01 to 0.68) | -5.42 to 1.14 | -2.89 (-5.52 to -0.26) | Unclear |
| Cotadutide 100 ug subcutaneous once daily COTA_SC_100UG_QD | -1.91 (-3.80 to 0.32) | -4.30 to 0.82 | -2.07 (-3.95 to -0.19) | Unclear |
| Semaglutide 0.5 mg subcutaneous once weekly SEMA_SC_0p5MG_QW | -1.84 (-4.00 to 0.91) | -4.44 to 1.37 | -2.26 (-4.61 to 0.10) | Unclear |
| Cotadutide 200 ug subcutaneous once daily COTA_SC_200UG_QD | -1.80 (-3.53 to 0.26) | -4.04 to 0.89 | -1.96 (-3.64 to -0.28) | Unclear |
| Empagliflozin EMPAGLIFLOZIN | -1.50 (-6.58 to 3.87) | -6.78 to 4.15 | -2.32 (-7.62 to 2.99) | Unclear |
| Liraglutide 1.8 mg subcutaneous once daily LIRA_SC_1p8MG_QD | -1.34 (-3.01 to 0.84) | -3.41 to 1.46 | -1.62 (-3.43 to 0.20) | Unclear |
| Taspoglutide 20 mg subcutaneous once weekly TASP_SC_20MG_QW | -1.18 (-3.65 to 1.94) | -4.05 to 2.36 | -1.54 (-4.16 to 1.09) | Unclear |
| Semaglutide oral once daily (original tablet), flexible dose: 3, 7 or 14 mg adjusted by HbA1c and tolerability SEMA_PO_FLEX_QD | -0.99 (-3.64 to 2.39) | -4.06 to 2.80 | -1.34 (-4.16 to 1.48) | Unclear |
| Liraglutide 1.2 mg subcutaneous once daily LIRA_SC_1p2MG_QD | -0.70 (-2.89 to 2.11) | -3.25 to 2.67 | -0.99 (-3.28 to 1.31) | Unclear |
| Liraglutide and empagliflozin 1.8 to 25 mg injection once daily EMPALIRA_SC_1p8-25MG_QD | -0.40 (-5.41 to 4.75) | -5.56 to 4.94 | -1.22 (-6.34 to 3.91) | Unclear |
| Taspoglutide 10 mg subcutaneous once weekly TASP_SC_10MG_QW | -0.39 (-2.92 to 2.79) | -3.32 to 3.21 | -0.74 (-3.36 to 1.89) | Unclear |
| Dulaglutide 1.5 mg subcutaneous once weekly DULA_SC_1p5MG_QW | -0.14 (-2.45 to 2.80) | -2.86 to 3.31 | -0.61 (-3.12 to 1.89) | Unclear |
| Dulaglutide 0.75 mg subcutaneous once weekly DULA_SC_0p75MG_QW | 0.33 (-2.01 to 3.28) | -2.42 to 3.69 | -0.13 (-2.63 to 2.38) | Unclear |
| Sitagliptin SITAGLIPTIN | 0.72 (-1.28 to 3.25) | -1.78 to 3.88 | 0.36 (-1.83 to 2.55) | Unclear |
| Insulin icodec and semaglutide (IcoSema) subcutaneous once weekly titrated ICOSEMA_SC_TIT_QW | 0.78 (-1.77 to 3.79) | -2.17 to 4.22 | 0.37 (-2.26 to 3.00) | Unclear |
| Liraglutide 0.9 mg injection once daily LIRA_SC_0p9MG_QD | 1.05 (-0.73 to 2.78) | -1.38 to 3.44 | 1.04 (-0.36 to 2.44) | Unclear |
| Liraglutide 0.6 mg subcutaneous once daily LIRA_SC_0p6MG_QD | 1.14 (-0.64 to 2.93) | -1.32 to 3.55 | 1.13 (-0.26 to 2.52) | Unclear |
| Basal insulin OTHER_ACTIVE_basal_insulin | 1.37 (-3.50 to 6.55) | -3.65 to 6.74 | 0.58 (-4.54 to 5.71) | Unclear |
| Insulin glargine INS_GLARGINE | 2.45 (-0.02 to 5.60) | -0.39 to 6.08 | 1.90 (-0.81 to 4.61) | Unclear |
| Insulin degludec and liraglutide (IDegLira) subcutaneous once daily titrated IDEGLIRA_SC_TIT_QD | 2.51 (0.41 to 5.38) | -0.03 to 5.86 | 2.28 (0.05 to 4.52) | Worse |
| Insulin degludec INS_DEGLUDEC | 3.73 (1.53 to 6.54) | 1.16 to 7.05 | 3.48 (1.22 to 5.75) | Worse |
Ranking
How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.
League table
Every treatment against every other: mean difference of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.
| Row versus column | PLACEBO | TIRZ_SC_15MG_QW | SEMA_SC_16MG_QW | TIRZ_SC_10MG_QW | SEMA_SC_8MG_QW | SEMA_SC_2p0MG_QW | TIRZ_SC_5MG_QW | SEMA_SC_1p0MG_QW | COTA_SC_300UG_QD | CANAGLIFLOZIN | COTA_SC_100UG_QD | SEMA_SC_0p5MG_QW | COTA_SC_200UG_QD | EMPAGLIFLOZIN | LIRA_SC_1p8MG_QD | TASP_SC_20MG_QW | SEMA_PO_FLEX_QD | LIRA_SC_1p2MG_QD | EMPALIRA_SC_1p8-25MG_QD | TASP_SC_10MG_QW | DULA_SC_1p5MG_QW | DULA_SC_0p75MG_QW | SITAGLIPTIN | ICOSEMA_SC_TIT_QW | LIRA_SC_0p9MG_QD | LIRA_SC_0p6MG_QD | OTHER_ACTIVE_basal_insulin | INS_GLARGINE | IDEGLIRA_SC_TIT_QD | INS_DEGLUDEC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLACEBO | PLACEBO | 11.38 7.82 to 14.21 | 10.60 7.54 to 13.47 | 9.00 5.35 to 11.73 | 7.61 4.92 to 10.38 | 6.41 3.49 to 9.36 | 6.14 2.42 to 8.83 | 3.86 1.33 to 5.92 | 3.06 0.98 to 4.84 | 2.46 -0.68 to 5.01 | 1.91 -0.32 to 3.80 | 1.84 -0.91 to 4.00 | 1.80 -0.26 to 3.53 | 1.50 -3.87 to 6.58 | 1.34 -0.84 to 3.01 | 1.18 -1.94 to 3.65 | 0.99 -2.39 to 3.64 | 0.70 -2.11 to 2.89 | 0.40 -4.75 to 5.41 | 0.39 -2.79 to 2.92 | 0.14 -2.80 to 2.45 | -0.33 -3.28 to 2.01 | -0.72 -3.25 to 1.28 | -0.78 -3.79 to 1.77 | -1.05 -2.78 to 0.73 | -1.14 -2.93 to 0.64 | -1.37 -6.55 to 3.50 | -2.45 -5.60 to 0.02 | -2.51 -5.38 to -0.41 | -3.73 -6.54 to -1.53 |
| TIRZ_SC_15MG_QW | -11.38 -14.21 to -7.82 | TIRZ_SC_15MG_QW | -0.78 -4.86 to 3.72 | -2.37 -3.80 to -1.03 | -3.76 -7.61 to 0.63 | -4.92 -8.96 to -0.34 | -5.26 -6.75 to -4.02 | -7.52 -9.86 to -4.84 | -8.33 -11.39 to -4.83 | -8.93 -11.74 to -5.71 | -9.45 -12.62 to -5.88 | -9.56 -11.92 to -6.91 | -9.56 -12.58 to -6.06 | -9.78 -15.47 to -4.27 | -10.03 -12.77 to -7.24 | -10.20 -13.40 to -6.84 | -10.39 -13.72 to -6.99 | -10.73 -13.68 to -7.43 | -10.90 -16.37 to -5.56 | -11.01 -14.17 to -7.79 | -11.25 -13.46 to -8.91 | -11.72 -13.86 to -9.38 | -12.11 -14.75 to -9.23 | -12.19 -14.98 to -9.02 | -12.45 -15.63 to -8.36 | -12.53 -15.69 to -8.36 | -12.69 -18.10 to -7.28 | -13.81 -15.41 to -12.21 | -13.90 -17.00 to -10.67 | -15.12 -18.22 to -11.87 |
| SEMA_SC_16MG_QW | -10.60 -13.47 to -7.54 | 0.78 -3.72 to 4.86 | SEMA_SC_16MG_QW | -1.60 -6.08 to 2.54 | -2.96 -6.32 to 0.36 | -4.15 -7.61 to -0.64 | -4.51 -9.21 to -0.41 | -6.76 -10.57 to -3.15 | -7.56 -11.12 to -4.07 | -8.13 -12.32 to -4.20 | -8.70 -12.39 to -5.12 | -8.77 -12.77 to -5.06 | -8.78 -12.43 to -5.34 | -9.09 -15.22 to -3.13 | -9.27 -12.99 to -5.91 | -9.41 -13.64 to -5.63 | -9.62 -14.01 to -5.56 | -9.95 -13.91 to -6.32 | -10.16 -16.22 to -4.38 | -10.25 -14.43 to -6.27 | -10.46 -14.67 to -6.66 | -10.96 -15.03 to -7.12 | -11.34 -15.13 to -7.77 | -11.40 -15.55 to -7.43 | -11.65 -14.99 to -8.14 | -11.75 -15.01 to -8.26 | -11.94 -18.02 to -6.26 | -13.04 -17.39 to -9.12 | -13.13 -17.20 to -9.47 | -14.35 -18.41 to -10.69 |
| TIRZ_SC_10MG_QW | -9.00 -11.73 to -5.35 | 2.37 1.03 to 3.80 | 1.60 -2.54 to 6.08 | TIRZ_SC_10MG_QW | -1.38 -5.21 to 3.09 | -2.56 -6.48 to 2.10 | -2.89 -4.37 to -1.60 | -5.15 -7.44 to -2.43 | -5.94 -8.92 to -2.39 | -6.56 -9.31 to -3.38 | -7.09 -10.30 to -3.47 | -7.18 -9.48 to -4.51 | -7.18 -10.17 to -3.71 | -7.42 -13.09 to -1.87 | -7.65 -10.26 to -4.86 | -7.83 -10.94 to -4.51 | -8.04 -11.25 to -4.56 | -8.33 -11.34 to -5.07 | -8.52 -13.97 to -3.11 | -8.64 -11.59 to -5.34 | -8.87 -10.93 to -6.46 | -9.34 -11.39 to -6.94 | -9.73 -12.32 to -6.89 | -9.81 -12.58 to -6.52 | -10.07 -13.25 to -5.87 | -10.17 -13.32 to -5.90 | -10.29 -15.76 to -4.91 | -11.44 -12.93 to -9.78 | -11.52 -14.56 to -8.26 | -12.74 -15.74 to -9.45 |
| SEMA_SC_8MG_QW | -7.61 -10.38 to -4.92 | 3.76 -0.63 to 7.61 | 2.96 -0.36 to 6.32 | 1.38 -3.09 to 5.21 | SEMA_SC_8MG_QW | -1.21 -4.49 to 2.06 | -1.51 -6.02 to 2.28 | -3.76 -7.50 to -0.37 | -4.55 -7.97 to -1.33 | -5.14 -9.37 to -1.50 | -5.72 -9.32 to -2.42 | -5.80 -9.56 to -2.40 | -5.82 -9.31 to -2.56 | -6.14 -12.20 to -0.51 | -6.26 -9.85 to -3.24 | -6.44 -10.58 to -2.71 | -6.67 -11.03 to -2.75 | -6.95 -10.80 to -3.50 | -7.21 -13.08 to -1.52 | -7.24 -11.47 to -3.59 | -7.49 -11.48 to -3.89 | -7.95 -11.99 to -4.44 | -8.35 -12.12 to -5.03 | -8.41 -12.55 to -4.77 | -8.66 -11.87 to -5.50 | -8.76 -11.91 to -5.55 | -9.01 -14.87 to -3.36 | -10.07 -14.16 to -6.35 | -10.13 -14.03 to -6.78 | -11.34 -15.31 to -7.94 |
| SEMA_SC_2p0MG_QW | -6.41 -9.36 to -3.49 | 4.92 0.34 to 8.96 | 4.15 0.64 to 7.61 | 2.56 -2.10 to 6.48 | 1.21 -2.06 to 4.49 | SEMA_SC_2p0MG_QW | -0.36 -5.19 to 3.58 | -2.59 -6.50 to 0.88 | -3.37 -6.99 to -0.06 | -3.97 -8.31 to -0.13 | -4.53 -8.15 to -1.13 | -4.62 -8.56 to -1.03 | -4.61 -8.25 to -1.34 | -4.91 -11.19 to 0.87 | -5.10 -8.75 to -1.88 | -5.25 -9.43 to -1.48 | -5.45 -9.75 to -1.52 | -5.80 -9.65 to -2.27 | -6.00 -12.21 to -0.38 | -6.07 -10.32 to -2.32 | -6.29 -10.48 to -2.66 | -6.78 -10.90 to -3.11 | -7.18 -11.00 to -3.76 | -7.19 -11.48 to -3.45 | -7.47 -10.80 to -4.13 | -7.56 -10.98 to -4.16 | -7.77 -13.79 to -2.21 | -8.88 -13.22 to -5.03 | -8.95 -12.95 to -5.50 | -10.17 -14.16 to -6.67 |
| TIRZ_SC_5MG_QW | -6.14 -8.83 to -2.42 | 5.26 4.02 to 6.75 | 4.51 0.41 to 9.21 | 2.89 1.60 to 4.37 | 1.51 -2.28 to 6.02 | 0.36 -3.58 to 5.19 | TIRZ_SC_5MG_QW | -2.29 -4.45 to 0.59 | -3.08 -5.97 to 0.51 | -3.68 -6.40 to -0.30 | -4.20 -7.26 to -0.36 | -4.31 -6.51 to -1.55 | -4.31 -7.26 to -0.69 | -4.55 -10.12 to 1.12 | -4.79 -7.29 to -1.82 | -4.96 -7.97 to -1.47 | -5.16 -8.24 to -1.54 | -5.46 -8.22 to -2.09 | -5.65 -11.02 to -0.21 | -5.77 -8.75 to -2.26 | -6.00 -7.97 to -3.44 | -6.48 -8.41 to -3.99 | -6.87 -9.30 to -3.91 | -6.95 -9.62 to -3.42 | -7.19 -10.26 to -2.85 | -7.27 -10.33 to -2.84 | -7.43 -12.74 to -1.93 | -8.56 -9.92 to -6.76 | -8.66 -11.55 to -5.23 | -9.88 -12.73 to -6.46 |
| SEMA_SC_1p0MG_QW | -3.86 -5.92 to -1.33 | 7.52 4.84 to 9.86 | 6.76 3.15 to 10.57 | 5.15 2.43 to 7.44 | 3.76 0.37 to 7.50 | 2.59 -0.88 to 6.50 | 2.29 -0.59 to 4.45 | SEMA_SC_1p0MG_QW | -0.80 -3.06 to 1.57 | -1.39 -3.13 to 0.33 | -1.93 -4.43 to 0.59 | -2.02 -3.31 to -0.86 | -2.04 -4.26 to 0.32 | -2.29 -7.64 to 2.66 | -2.50 -4.12 to -1.11 | -2.67 -4.99 to -0.49 | -2.86 -5.32 to -0.57 | -3.18 -5.21 to -1.21 | -3.42 -8.44 to 1.55 | -3.47 -5.77 to -1.26 | -3.72 -5.31 to -2.30 | -4.18 -5.80 to -2.74 | -4.57 -6.04 to -3.29 | -4.66 -6.38 to -2.82 | -4.91 -7.52 to -1.65 | -5.00 -7.64 to -1.81 | -5.17 -10.23 to -0.36 | -6.27 -8.44 to -4.46 | -6.38 -8.68 to -4.27 | -7.59 -9.98 to -5.36 |
| COTA_SC_300UG_QD | -3.06 -4.84 to -0.98 | 8.33 4.83 to 11.39 | 7.56 4.07 to 11.12 | 5.94 2.39 to 8.92 | 4.55 1.33 to 7.97 | 3.37 0.06 to 6.99 | 3.08 -0.51 to 5.97 | 0.80 -1.57 to 3.06 | COTA_SC_300UG_QD | -0.59 -3.58 to 2.22 | -1.15 -3.12 to 0.86 | -1.23 -3.84 to 1.18 | -1.25 -3.09 to 0.55 | -1.54 -6.91 to 3.66 | -1.71 -3.81 to 0.02 | -1.88 -4.96 to 0.88 | -2.05 -5.45 to 0.80 | -2.39 -5.05 to -0.02 | -2.66 -7.76 to 2.39 | -2.68 -5.75 to 0.06 | -2.92 -5.72 to -0.38 | -3.40 -6.15 to -0.83 | -3.78 -6.35 to -1.56 | -3.85 -6.88 to -0.99 | -4.11 -6.57 to -1.24 | -4.21 -6.55 to -1.47 | -4.43 -9.63 to 0.55 | -5.49 -8.62 to -2.74 | -5.58 -8.27 to -3.16 | -6.79 -9.50 to -4.40 |
| CANAGLIFLOZIN | -2.46 -5.01 to 0.68 | 8.93 5.71 to 11.74 | 8.13 4.20 to 12.32 | 6.56 3.38 to 9.31 | 5.14 1.50 to 9.37 | 3.97 0.13 to 8.31 | 3.68 0.30 to 6.40 | 1.39 -0.33 to 3.13 | 0.59 -2.22 to 3.58 | CANAGLIFLOZIN | -0.53 -3.47 to 2.52 | -0.63 -2.79 to 1.44 | -0.65 -3.39 to 2.23 | -0.89 -6.49 to 4.35 | -1.10 -3.42 to 1.07 | -1.28 -4.25 to 1.42 | -1.46 -4.45 to 1.34 | -1.78 -4.49 to 0.80 | -2.05 -7.33 to 3.11 | -2.08 -5.04 to 0.75 | -2.32 -4.66 to -0.08 | -2.78 -5.15 to -0.54 | -3.18 -5.41 to -1.02 | -3.27 -5.64 to -0.71 | -3.50 -6.52 to 0.26 | -3.61 -6.60 to 0.11 | -3.79 -8.99 to 1.23 | -4.87 -7.72 to -2.39 | -4.98 -7.83 to -2.34 | -6.17 -9.20 to -3.52 |
| COTA_SC_100UG_QD | -1.91 -3.80 to 0.32 | 9.45 5.88 to 12.62 | 8.70 5.12 to 12.39 | 7.09 3.47 to 10.30 | 5.72 2.42 to 9.32 | 4.53 1.13 to 8.15 | 4.20 0.36 to 7.26 | 1.93 -0.59 to 4.43 | 1.15 -0.86 to 3.12 | 0.53 -2.52 to 3.47 | COTA_SC_100UG_QD | -0.07 -2.80 to 2.43 | -0.10 -2.08 to 1.94 | -0.38 -5.92 to 4.80 | -0.57 -2.84 to 1.43 | -0.72 -3.92 to 2.11 | -0.92 -4.30 to 2.08 | -1.25 -4.04 to 1.29 | -1.50 -6.78 to 3.76 | -1.55 -4.68 to 1.32 | -1.79 -4.72 to 0.98 | -2.25 -5.22 to 0.51 | -2.64 -5.19 to -0.22 | -2.73 -5.77 to 0.25 | -2.97 -5.51 to -0.01 | -3.07 -5.53 to -0.10 | -3.24 -8.51 to 1.75 | -4.34 -7.57 to -1.47 | -4.43 -7.26 to -1.92 | -5.63 -8.45 to -3.11 |
| SEMA_SC_0p5MG_QW | -1.84 -4.00 to 0.91 | 9.56 6.91 to 11.92 | 8.77 5.06 to 12.77 | 7.18 4.51 to 9.48 | 5.80 2.40 to 9.56 | 4.62 1.03 to 8.56 | 4.31 1.55 to 6.51 | 2.02 0.86 to 3.31 | 1.23 -1.18 to 3.84 | 0.63 -1.44 to 2.79 | 0.07 -2.43 to 2.80 | SEMA_SC_0p5MG_QW | -0.03 -2.35 to 2.55 | -0.27 -5.57 to 4.84 | -0.48 -2.26 to 1.16 | -0.64 -3.06 to 1.62 | -0.84 -3.33 to 1.60 | -1.16 -3.31 to 0.99 | -1.39 -6.48 to 3.71 | -1.44 -3.78 to 0.83 | -1.69 -3.17 to -0.21 | -2.15 -3.68 to -0.68 | -2.55 -4.11 to -1.08 | -2.63 -4.68 to -0.40 | -2.88 -5.61 to 0.51 | -2.98 -5.64 to 0.31 | -3.13 -8.17 to 1.80 | -4.26 -6.34 to -2.41 | -4.35 -6.77 to -2.04 | -5.55 -8.08 to -3.13 |
| COTA_SC_200UG_QD | -1.80 -3.53 to 0.26 | 9.56 6.06 to 12.58 | 8.78 5.34 to 12.43 | 7.18 3.71 to 10.17 | 5.82 2.56 to 9.31 | 4.61 1.34 to 8.25 | 4.31 0.69 to 7.26 | 2.04 -0.32 to 4.26 | 1.25 -0.55 to 3.09 | 0.65 -2.23 to 3.39 | 0.10 -1.94 to 2.08 | 0.03 -2.55 to 2.35 | COTA_SC_200UG_QD | -0.31 -5.62 to 4.79 | -0.46 -2.52 to 1.30 | -0.62 -3.70 to 2.04 | -0.83 -4.09 to 2.05 | -1.14 -3.78 to 1.25 | -1.40 -6.53 to 3.67 | -1.44 -4.48 to 1.35 | -1.69 -4.43 to 0.88 | -2.14 -4.90 to 0.37 | -2.53 -4.95 to -0.29 | -2.61 -5.52 to 0.26 | -2.86 -5.25 to -0.04 | -2.96 -5.32 to -0.15 | -3.18 -8.17 to 1.77 | -4.25 -7.29 to -1.56 | -4.33 -6.93 to -2.00 | -5.53 -8.16 to -3.18 |
| EMPAGLIFLOZIN | -1.50 -6.58 to 3.87 | 9.78 4.27 to 15.47 | 9.09 3.13 to 15.22 | 7.42 1.87 to 13.09 | 6.14 0.51 to 12.20 | 4.91 -0.87 to 11.19 | 4.55 -1.12 to 10.12 | 2.29 -2.66 to 7.64 | 1.54 -3.66 to 6.91 | 0.89 -4.35 to 6.49 | 0.38 -4.80 to 5.92 | 0.27 -4.84 to 5.57 | 0.31 -4.79 to 5.62 | EMPAGLIFLOZIN | -0.22 -5.10 to 4.80 | -0.38 -5.57 to 5.20 | -0.55 -5.95 to 5.03 | -0.89 -5.98 to 4.48 | -1.06 -5.63 to 3.32 | -1.21 -6.36 to 4.27 | -1.40 -6.67 to 4.00 | -1.86 -7.03 to 3.43 | -2.29 -7.28 to 2.90 | -2.35 -7.58 to 3.08 | -2.55 -7.84 to 3.10 | -2.62 -7.97 to 3.04 | -2.88 -7.25 to 1.63 | -4.00 -9.37 to 1.39 | -4.09 -9.19 to 1.24 | -5.28 -10.41 to 0.04 |
| LIRA_SC_1p8MG_QD | -1.34 -3.01 to 0.84 | 10.03 7.24 to 12.77 | 9.27 5.91 to 12.99 | 7.65 4.86 to 10.26 | 6.26 3.24 to 9.85 | 5.10 1.88 to 8.75 | 4.79 1.82 to 7.29 | 2.50 1.11 to 4.12 | 1.71 -0.02 to 3.81 | 1.10 -1.07 to 3.42 | 0.57 -1.43 to 2.84 | 0.48 -1.16 to 2.26 | 0.46 -1.30 to 2.52 | 0.22 -4.80 to 5.10 | LIRA_SC_1p8MG_QD | -0.16 -2.34 to 2.10 | -0.36 -2.84 to 2.13 | -0.68 -2.34 to 1.11 | -0.87 -5.63 to 3.84 | -0.99 -3.20 to 1.30 | -1.22 -3.18 to 0.87 | -1.69 -3.69 to 0.34 | -2.07 -3.46 to -0.57 | -2.16 -4.29 to 0.27 | -2.41 -4.60 to 0.59 | -2.50 -4.70 to 0.52 | -2.65 -7.41 to 1.95 | -3.79 -6.11 to -1.47 | -3.88 -5.55 to -2.21 | -5.07 -6.79 to -3.33 |
| TASP_SC_20MG_QW | -1.18 -3.65 to 1.94 | 10.20 6.84 to 13.40 | 9.41 5.63 to 13.64 | 7.83 4.51 to 10.94 | 6.44 2.71 to 10.58 | 5.25 1.48 to 9.43 | 4.96 1.47 to 7.97 | 2.67 0.49 to 4.99 | 1.88 -0.88 to 4.96 | 1.28 -1.42 to 4.25 | 0.72 -2.11 to 3.92 | 0.64 -1.62 to 3.06 | 0.62 -2.04 to 3.70 | 0.38 -5.20 to 5.57 | 0.16 -2.10 to 2.34 | TASP_SC_20MG_QW | -0.19 -2.88 to 2.55 | -0.51 -2.93 to 1.92 | -0.72 -6.04 to 4.46 | -0.81 -2.67 to 1.05 | -1.06 -3.64 to 1.64 | -1.53 -4.14 to 1.08 | -1.92 -3.69 to -0.07 | -2.00 -4.71 to 0.94 | -2.25 -5.22 to 1.53 | -2.34 -5.29 to 1.30 | -2.46 -7.70 to 2.51 | -3.62 -6.52 to -0.79 | -3.72 -6.47 to -1.01 | -4.92 -7.73 to -2.08 |
| SEMA_PO_FLEX_QD | -0.99 -3.64 to 2.39 | 10.39 6.99 to 13.72 | 9.62 5.56 to 14.01 | 8.04 4.56 to 11.25 | 6.67 2.75 to 11.03 | 5.45 1.52 to 9.75 | 5.16 1.54 to 8.24 | 2.86 0.57 to 5.32 | 2.05 -0.80 to 5.45 | 1.46 -1.34 to 4.45 | 0.92 -2.08 to 4.30 | 0.84 -1.60 to 3.33 | 0.83 -2.05 to 4.09 | 0.55 -5.03 to 5.95 | 0.36 -2.13 to 2.84 | 0.19 -2.55 to 2.88 | SEMA_PO_FLEX_QD | -0.31 -3.01 to 2.33 | -0.55 -5.96 to 4.79 | -0.60 -3.33 to 2.03 | -0.86 -3.54 to 1.95 | -1.33 -4.08 to 1.47 | -1.72 -3.70 to 0.34 | -1.79 -4.67 to 1.29 | -2.05 -5.10 to 1.84 | -2.15 -5.18 to 1.78 | -2.29 -7.60 to 2.77 | -3.42 -6.53 to -0.42 | -3.52 -6.43 to -0.51 | -4.72 -7.74 to -1.67 |
| LIRA_SC_1p2MG_QD | -0.70 -2.89 to 2.11 | 10.73 7.43 to 13.68 | 9.95 6.32 to 13.91 | 8.33 5.07 to 11.34 | 6.95 3.50 to 10.80 | 5.80 2.27 to 9.65 | 5.46 2.09 to 8.22 | 3.18 1.21 to 5.21 | 2.39 0.02 to 5.05 | 1.78 -0.80 to 4.49 | 1.25 -1.29 to 4.04 | 1.16 -0.99 to 3.31 | 1.14 -1.25 to 3.78 | 0.89 -4.48 to 5.98 | 0.68 -1.11 to 2.34 | 0.51 -1.92 to 2.93 | 0.31 -2.33 to 3.01 | LIRA_SC_1p2MG_QD | -0.21 -5.30 to 4.82 | -0.29 -2.80 to 2.13 | -0.53 -2.95 to 1.86 | -1.01 -3.53 to 1.31 | -1.39 -3.13 to 0.33 | -1.48 -4.07 to 1.31 | -1.74 -4.35 to 1.62 | -1.84 -4.47 to 1.56 | -1.95 -7.01 to 2.92 | -3.11 -5.91 to -0.48 | -3.19 -5.60 to -0.83 | -4.40 -6.84 to -1.98 |
| EMPALIRA_SC_1p8-25MG_QD | -0.40 -5.41 to 4.75 | 10.90 5.56 to 16.37 | 10.16 4.38 to 16.22 | 8.52 3.11 to 13.97 | 7.21 1.52 to 13.08 | 6.00 0.38 to 12.21 | 5.65 0.21 to 11.02 | 3.42 -1.55 to 8.44 | 2.66 -2.39 to 7.76 | 2.05 -3.11 to 7.33 | 1.50 -3.76 to 6.78 | 1.39 -3.71 to 6.48 | 1.40 -3.67 to 6.53 | 1.06 -3.32 to 5.63 | 0.87 -3.84 to 5.63 | 0.72 -4.46 to 6.04 | 0.55 -4.79 to 5.96 | 0.21 -4.82 to 5.30 | EMPALIRA_SC_1p8-25MG_QD | -0.09 -5.20 to 5.15 | -0.34 -5.46 to 4.83 | -0.79 -5.86 to 4.34 | -1.17 -6.12 to 3.82 | -1.24 -6.43 to 4.14 | -1.44 -6.66 to 4.18 | -1.55 -6.75 to 3.96 | -1.78 -5.90 to 2.45 | -2.91 -8.15 to 2.39 | -3.00 -7.90 to 2.04 | -4.19 -9.24 to 0.80 |
| TASP_SC_10MG_QW | -0.39 -2.92 to 2.79 | 11.01 7.79 to 14.17 | 10.25 6.27 to 14.43 | 8.64 5.34 to 11.59 | 7.24 3.59 to 11.47 | 6.07 2.32 to 10.32 | 5.77 2.26 to 8.75 | 3.47 1.26 to 5.77 | 2.68 -0.06 to 5.75 | 2.08 -0.75 to 5.04 | 1.55 -1.32 to 4.68 | 1.44 -0.83 to 3.78 | 1.44 -1.35 to 4.48 | 1.21 -4.27 to 6.36 | 0.99 -1.30 to 3.20 | 0.81 -1.05 to 2.67 | 0.60 -2.03 to 3.33 | 0.29 -2.13 to 2.80 | 0.09 -5.15 to 5.20 | TASP_SC_10MG_QW | -0.25 -2.78 to 2.29 | -0.71 -3.31 to 1.85 | -1.10 -2.86 to 0.66 | -1.17 -3.90 to 1.74 | -1.43 -4.38 to 2.29 | -1.52 -4.48 to 2.14 | -1.63 -7.01 to 3.30 | -2.80 -5.63 to -0.01 | -2.90 -5.62 to -0.16 | -4.10 -6.96 to -1.29 |
| DULA_SC_1p5MG_QW | -0.14 -2.45 to 2.80 | 11.25 8.91 to 13.46 | 10.46 6.66 to 14.67 | 8.87 6.46 to 10.93 | 7.49 3.89 to 11.48 | 6.29 2.66 to 10.48 | 6.00 3.44 to 7.97 | 3.72 2.30 to 5.31 | 2.92 0.38 to 5.72 | 2.32 0.08 to 4.66 | 1.79 -0.98 to 4.72 | 1.69 0.21 to 3.17 | 1.69 -0.88 to 4.43 | 1.40 -4.00 to 6.67 | 1.22 -0.87 to 3.18 | 1.06 -1.64 to 3.64 | 0.86 -1.95 to 3.54 | 0.53 -1.86 to 2.95 | 0.34 -4.83 to 5.46 | 0.25 -2.29 to 2.78 | DULA_SC_1p5MG_QW | -0.46 -1.67 to 0.77 | -0.84 -2.80 to 1.04 | -0.94 -3.18 to 1.45 | -1.19 -3.99 to 2.33 | -1.31 -4.12 to 2.18 | -1.43 -6.60 to 3.56 | -2.56 -4.29 to -1.08 | -2.64 -5.28 to -0.13 | -3.86 -6.44 to -1.34 |
| DULA_SC_0p75MG_QW | 0.33 -2.01 to 3.28 | 11.72 9.38 to 13.86 | 10.96 7.12 to 15.03 | 9.34 6.94 to 11.39 | 7.95 4.44 to 11.99 | 6.78 3.11 to 10.90 | 6.48 3.99 to 8.41 | 4.18 2.74 to 5.80 | 3.40 0.83 to 6.15 | 2.78 0.54 to 5.15 | 2.25 -0.51 to 5.22 | 2.15 0.68 to 3.68 | 2.14 -0.37 to 4.90 | 1.86 -3.43 to 7.03 | 1.69 -0.34 to 3.69 | 1.53 -1.08 to 4.14 | 1.33 -1.47 to 4.08 | 1.01 -1.31 to 3.53 | 0.79 -4.34 to 5.86 | 0.71 -1.85 to 3.31 | 0.46 -0.77 to 1.67 | DULA_SC_0p75MG_QW | -0.38 -2.29 to 1.52 | -0.47 -2.74 to 1.93 | -0.71 -3.57 to 2.88 | -0.82 -3.63 to 2.79 | -0.97 -6.20 to 4.00 | -2.10 -3.78 to -0.56 | -2.19 -4.79 to 0.39 | -3.39 -6.03 to -0.82 |
| SITAGLIPTIN | 0.72 -1.28 to 3.25 | 12.11 9.23 to 14.75 | 11.34 7.77 to 15.13 | 9.73 6.89 to 12.32 | 8.35 5.03 to 12.12 | 7.18 3.76 to 11.00 | 6.87 3.91 to 9.30 | 4.57 3.29 to 6.04 | 3.78 1.56 to 6.35 | 3.18 1.02 to 5.41 | 2.64 0.22 to 5.19 | 2.55 1.08 to 4.11 | 2.53 0.29 to 4.95 | 2.29 -2.90 to 7.28 | 2.07 0.57 to 3.46 | 1.92 0.07 to 3.69 | 1.72 -0.34 to 3.70 | 1.39 -0.33 to 3.13 | 1.17 -3.82 to 6.12 | 1.10 -0.66 to 2.86 | 0.84 -1.04 to 2.80 | 0.38 -1.52 to 2.29 | SITAGLIPTIN | -0.08 -2.22 to 2.24 | -0.33 -2.86 to 2.96 | -0.42 -2.91 to 2.79 | -0.57 -5.50 to 4.21 | -1.71 -4.01 to 0.47 | -1.80 -3.95 to 0.33 | -3.01 -5.27 to -0.80 |
| ICOSEMA_SC_TIT_QW | 0.78 -1.77 to 3.79 | 12.19 9.02 to 14.98 | 11.40 7.43 to 15.55 | 9.81 6.52 to 12.58 | 8.41 4.77 to 12.55 | 7.19 3.45 to 11.48 | 6.95 3.42 to 9.62 | 4.66 2.82 to 6.38 | 3.85 0.99 to 6.88 | 3.27 0.71 to 5.64 | 2.73 -0.25 to 5.77 | 2.63 0.40 to 4.68 | 2.61 -0.26 to 5.52 | 2.35 -3.08 to 7.58 | 2.16 -0.27 to 4.29 | 2.00 -0.94 to 4.71 | 1.79 -1.29 to 4.67 | 1.48 -1.31 to 4.07 | 1.24 -4.14 to 6.43 | 1.17 -1.74 to 3.90 | 0.94 -1.45 to 3.18 | 0.47 -1.93 to 2.74 | 0.08 -2.24 to 2.22 | ICOSEMA_SC_TIT_QW | -0.25 -3.39 to 3.30 | -0.36 -3.36 to 3.24 | -0.55 -5.79 to 4.48 | -1.62 -4.43 to 0.79 | -1.71 -4.73 to 0.98 | -2.92 -5.87 to -0.22 |
| LIRA_SC_0p9MG_QD | 1.05 -0.73 to 2.78 | 12.45 8.36 to 15.63 | 11.65 8.14 to 14.99 | 10.07 5.87 to 13.25 | 8.66 5.50 to 11.87 | 7.47 4.13 to 10.80 | 7.19 2.85 to 10.26 | 4.91 1.65 to 7.52 | 4.11 1.24 to 6.57 | 3.50 -0.26 to 6.52 | 2.97 0.01 to 5.51 | 2.88 -0.51 to 5.61 | 2.86 0.04 to 5.25 | 2.55 -3.10 to 7.84 | 2.41 -0.59 to 4.60 | 2.25 -1.53 to 5.22 | 2.05 -1.84 to 5.10 | 1.74 -1.62 to 4.35 | 1.44 -4.18 to 6.66 | 1.43 -2.29 to 4.38 | 1.19 -2.33 to 3.99 | 0.71 -2.88 to 3.57 | 0.33 -2.96 to 2.86 | 0.25 -3.30 to 3.39 | LIRA_SC_0p9MG_QD | -0.09 -1.82 to 1.63 | -0.31 -5.76 to 4.85 | -1.37 -5.12 to 1.54 | -1.46 -4.96 to 1.15 | -2.66 -6.15 to -0.05 |
| LIRA_SC_0p6MG_QD | 1.14 -0.64 to 2.93 | 12.53 8.36 to 15.69 | 11.75 8.26 to 15.01 | 10.17 5.90 to 13.32 | 8.76 5.55 to 11.91 | 7.56 4.16 to 10.98 | 7.27 2.84 to 10.33 | 5.00 1.81 to 7.64 | 4.21 1.47 to 6.55 | 3.61 -0.11 to 6.60 | 3.07 0.10 to 5.53 | 2.98 -0.31 to 5.64 | 2.96 0.15 to 5.32 | 2.62 -3.04 to 7.97 | 2.50 -0.52 to 4.70 | 2.34 -1.30 to 5.29 | 2.15 -1.78 to 5.18 | 1.84 -1.56 to 4.47 | 1.55 -3.96 to 6.75 | 1.52 -2.14 to 4.48 | 1.31 -2.18 to 4.12 | 0.82 -2.79 to 3.63 | 0.42 -2.79 to 2.91 | 0.36 -3.24 to 3.36 | 0.09 -1.63 to 1.82 | LIRA_SC_0p6MG_QD | -0.21 -5.66 to 5.01 | -1.28 -5.10 to 1.63 | -1.36 -4.77 to 1.23 | -2.57 -6.02 to 0.10 |
| OTHER_ACTIVE_basal_insulin | 1.37 -3.50 to 6.55 | 12.69 7.28 to 18.10 | 11.94 6.26 to 18.02 | 10.29 4.91 to 15.76 | 9.01 3.36 to 14.87 | 7.77 2.21 to 13.79 | 7.43 1.93 to 12.74 | 5.17 0.36 to 10.23 | 4.43 -0.55 to 9.63 | 3.79 -1.23 to 8.99 | 3.24 -1.75 to 8.51 | 3.13 -1.80 to 8.17 | 3.18 -1.77 to 8.17 | 2.88 -1.63 to 7.25 | 2.65 -1.95 to 7.41 | 2.46 -2.51 to 7.70 | 2.29 -2.77 to 7.60 | 1.95 -2.92 to 7.01 | 1.78 -2.45 to 5.90 | 1.63 -3.30 to 7.01 | 1.43 -3.56 to 6.60 | 0.97 -4.00 to 6.20 | 0.57 -4.21 to 5.50 | 0.55 -4.48 to 5.79 | 0.31 -4.85 to 5.76 | 0.21 -5.01 to 5.66 | OTHER_ACTIVE_basal_insulin | -1.15 -6.33 to 4.19 | -1.20 -6.05 to 3.80 | -2.39 -7.35 to 2.60 |
| INS_GLARGINE | 2.45 -0.02 to 5.60 | 13.81 12.21 to 15.41 | 13.04 9.12 to 17.39 | 11.44 9.78 to 12.93 | 10.07 6.35 to 14.16 | 8.88 5.03 to 13.22 | 8.56 6.76 to 9.92 | 6.27 4.46 to 8.44 | 5.49 2.74 to 8.62 | 4.87 2.39 to 7.72 | 4.34 1.47 to 7.57 | 4.26 2.41 to 6.34 | 4.25 1.56 to 7.29 | 4.00 -1.39 to 9.37 | 3.79 1.47 to 6.11 | 3.62 0.79 to 6.52 | 3.42 0.42 to 6.53 | 3.11 0.48 to 5.91 | 2.91 -2.39 to 8.15 | 2.80 0.01 to 5.63 | 2.56 1.08 to 4.29 | 2.10 0.56 to 3.78 | 1.71 -0.47 to 4.01 | 1.62 -0.79 to 4.43 | 1.37 -1.54 to 5.12 | 1.28 -1.63 to 5.10 | 1.15 -4.19 to 6.33 | INS_GLARGINE | -0.11 -2.85 to 2.69 | -1.29 -4.04 to 1.57 |
| IDEGLIRA_SC_TIT_QD | 2.51 0.41 to 5.38 | 13.90 10.67 to 17.00 | 13.13 9.47 to 17.20 | 11.52 8.26 to 14.56 | 10.13 6.78 to 14.03 | 8.95 5.50 to 12.95 | 8.66 5.23 to 11.55 | 6.38 4.27 to 8.68 | 5.58 3.16 to 8.27 | 4.98 2.34 to 7.83 | 4.43 1.92 to 7.26 | 4.35 2.04 to 6.77 | 4.33 2.00 to 6.93 | 4.09 -1.24 to 9.19 | 3.88 2.21 to 5.55 | 3.72 1.01 to 6.47 | 3.52 0.51 to 6.43 | 3.19 0.83 to 5.60 | 3.00 -2.04 to 7.90 | 2.90 0.16 to 5.62 | 2.64 0.13 to 5.28 | 2.19 -0.39 to 4.79 | 1.80 -0.33 to 3.95 | 1.71 -0.98 to 4.73 | 1.46 -1.15 to 4.96 | 1.36 -1.23 to 4.77 | 1.20 -3.80 to 6.05 | 0.11 -2.69 to 2.85 | IDEGLIRA_SC_TIT_QD | -1.20 -2.90 to 0.48 |
| INS_DEGLUDEC | 3.73 1.53 to 6.54 | 15.12 11.87 to 18.22 | 14.35 10.69 to 18.41 | 12.74 9.45 to 15.74 | 11.34 7.94 to 15.31 | 10.17 6.67 to 14.16 | 9.88 6.46 to 12.73 | 7.59 5.36 to 9.98 | 6.79 4.40 to 9.50 | 6.17 3.52 to 9.20 | 5.63 3.11 to 8.45 | 5.55 3.13 to 8.08 | 5.53 3.18 to 8.16 | 5.28 -0.04 to 10.41 | 5.07 3.33 to 6.79 | 4.92 2.08 to 7.73 | 4.72 1.67 to 7.74 | 4.40 1.98 to 6.84 | 4.19 -0.80 to 9.24 | 4.10 1.29 to 6.96 | 3.86 1.34 to 6.44 | 3.39 0.82 to 6.03 | 3.01 0.80 to 5.27 | 2.92 0.22 to 5.87 | 2.66 0.05 to 6.15 | 2.57 -0.10 to 6.02 | 2.39 -2.60 to 7.35 | 1.29 -1.57 to 4.04 | 1.20 -0.48 to 2.90 | INS_DEGLUDEC |
Heterogeneity, fit and convergence
Bayesian random effects (primary)
Frequentist check (netmeta)
Inconsistency
Do trials comparing two treatments directly agree with the indirect evidence through other treatments?
No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting; the between designs Q above is the global check.
Small study effects
A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.
Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.
Baseline characteristics of the trials
The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.
| Trial | Baseline BMI or body weight (kg/m2) effect modifier, prognostic factor; 14 of 17 | Sex (percent female) effect modifier, prognostic factor; 16 of 17 | Background glucose lowering therapy (stratum S0 to S4) effect modifier, prognostic factor; 17 of 17 | Asian ancestry or region (percent Asian) effect modifier, prognostic factor; 14 of 17 | Kidney function (eGFR) (mL/min/1.73 m2) prognostic factor, effect modifier; 4 of 17 | Treatment duration (weeks) effect modifier; 17 of 17 | Lifestyle co-intervention intensity (none standard intensive) effect modifier, prognostic factor; 17 of 17 |
|---|---|---|---|---|---|---|---|
| NCT00754988 S000027 | 32.47 | 44.91 | S1 | 8.82 | not reported | 156 | none |
| COMBINE 2 S000155 | 31.11 | 41.87 | S1 | 27.65 | not reported | 52 | not_reported |
| NCT03235050 S000257 | not reported | 53.72 | S1 | 0.72 | not reported | 54 | not_reported |
| SUSTAIN 7 S000372 | 33.5 | 55.12 | S1 | 15.9 | not reported | 40 | not_reported |
| NCT03878706 S000665 | 30 | 28.12 | S1 | not reported | 84.75 | 52.14 | not_reported |
| NCT00395746 S000862 | 24.87 | 36 | S1 | 100 region: all sites in Asia | not reported | 52 | not_reported |
| PIONEER 7 S001153 | 31.19 | 43.45 | S1 | 15.08 | 94.36 | 104 | not_reported |
| SURPASS-4 S001287 | 32.6 | 37.51 | S1 | 3.5 | 81.3 | 104 | not_reported |
| NCT03861039 S001385 | not reported | 24.15 | S1 | 100 | not reported | 52 | not_reported |
| AWARD-CHN2 S001404 | 26.77 | 44.77 | S1 | 81.52 | not reported | 52 | not_reported |
| NCT05486065 S001555 | 37.65 | 48.69 | S1 | 1.49 | not reported | 40 | not_reported |
| SUSTAIN 8 S001847 | not reported | 46.19 | S1 | 15.86 | not reported | 52 | not_reported |
| SUSTAIN™ 2 S001876 | 32.5 | not reported | S1 | 25.1 | 97.5 | 56 | not_reported |
| DUAL™ I Japan S001965 | 26.4 | 29.07 | S1 | 100 region: all sites in Asia | not reported | 52 | not_reported |
| NCT00700817 S002361 | 32.77 | 47.07 | S1 | 1.65 | not reported | 26 | not_reported |
| S002969 S002969 | 36.76 median | 77.78 | S1 | not reported | not reported | 26 | standard |
| S003432 S003432 | 34.45 | 56.85 | S1 | not reported | not reported | 52 | not_reported |
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- FlagBaseline, Baseline BMI or body weight: design means range from 24.9 (LIRA_SC_0p6MG_QD vs LIRA_SC_0p9MG_QD vs PLACEBO) to 37.7 (PLACEBO vs SEMA_SC_16MG_QW vs SEMA_SC_2p0MG_QW vs SEMA_SC_8MG_QW) kg/m2; threshold 3
- FlagBaseline, Sex: design means range from 24.2 (TIRZ_SC_10MG_QW vs TIRZ_SC_15MG_QW vs TIRZ_SC_5MG_QW) to 77.8 (LIRA_SC_1p8MG_QD vs PLACEBO) percent female; threshold 15
- FlagBaseline, Asian ancestry or region: design means range from 0.7 (COTA_SC_100UG_QD vs COTA_SC_200UG_QD vs COTA_SC_300UG_QD vs LIRA_SC_1p8MG_QD vs PLACEBO) to 100.0 (IDEGLIRA_SC_TIT_QD vs INS_DEGLUDEC vs LIRA_SC_1p8MG_QD) percent Asian; threshold 30
- FlagBaseline, Kidney function (eGFR): not reported by 13 of 17 trials
- FlagBaseline, Kidney function (eGFR): design means range from 81.3 (INS_GLARGINE vs TIRZ_SC_10MG_QW vs TIRZ_SC_15MG_QW vs TIRZ_SC_5MG_QW) to 97.5 (SEMA_SC_0p5MG_QW vs SEMA_SC_1p0MG_QW vs SITAGLIPTIN) mL/min/1.73 m2; threshold 15
- FlagBaseline, Treatment duration: design means range from 26.0 (LIRA_SC_1p2MG_QD vs LIRA_SC_1p8MG_QD vs SITAGLIPTIN) to 156.0 (SITAGLIPTIN vs TASP_SC_10MG_QW vs TASP_SC_20MG_QW) weeks; threshold 26
- NoteOutcome assessment, time point: selected time points span 40 to 56 weeks
- NoteOutcome assessment, analysis set: mixed: completers 1, full_analysis 8, modified_itt 4, other 2, randomized 1, safety 1
- NoteOutcome assessment, definition: mixed: not stated 16, Observed HbA1c at 12 months, mean and SD 1
- NoteRisk of bias, blinding: mixed: double_blind 7, open_label 9, single_blind 1
- NoteRisk of bias, funding: mixed: industry 15, non_industry 2
- NoteData handling, input conversions: median_converted 2
| Trial | definition | time weeks | analysis set | start year | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00754988 | not stated | 52 | modified_itt | 2008 | not stated | not stated | not stated | not stated | not stated | double_blind | industry | age 18 to 75; HbA1c 7.0 to 10.0 percent; BMI 25 (23 Asian) to 45; metformin at least 1500 mg |
| COMBINE 2 | not stated | 52 | full_analysis | 2022 | not stated | not stated | not stated | not stated | not stated | open_label | industry | adults T2D on GLP-1 RA with or without oral drugs; HbA1c 7.0 to 10.0 percent |
| NCT03235050 | not stated | 54 | full_analysis | 2017 | not stated | not stated | not stated | not stated | not stated | double_blind | industry | age 18 or older; BMI 25 or higher; HbA1c 7.0 to 10.5 percent; on metformin |
| SUSTAIN 7 | not stated | 40 | full_analysis | 2016 | not stated | not stated | not stated | not stated | not stated | open_label | industry | age 18 or older; HbA1c 7.0 to 10.5 percent; eGFR 60 or higher; metformin background |
| NCT03878706 | Observed HbA1c at 12 months, mean and SD | 52.14 | completers | 2017 | not stated | not stated | not stated | not stated | not stated | single_blind | non_industry | T2D on metformin, HbA1c above 7 percent, high or very high CV risk, eGFR 60 or more |
| NCT00395746 | not stated | 52 | full_analysis | 2006 | not stated | not stated | not stated | not stated | not stated | double_blind | industry | age 20 or older; HbA1c 7.4 to 10.4 on one sulfonylurea |
| PIONEER 7 | not stated | 52 | randomized | 2016 | not stated | not stated | not stated | not stated | not stated | open_label | industry | age 18 or more; HbA1c 7.5 to 9.5 percent; one or two oral glucose lowering drugs |
| SURPASS-4 | not stated | 52 | modified_itt | 2018 | not stated | not stated | not stated | not stated | not stated | open_label | industry | age 18 or older; HbA1c 7.5 to 10.5 percent; BMI 25 or more; increased cardiovascular risk; 1 to 3 oral agents |
| NCT03861039 | not stated | 52 | modified_itt | 2019 | not stated | not stated | not stated | not stated | not stated | open_label | industry | Japanese adults 20 y or older; BMI 23 or more; on OAM monotherapy |
| AWARD-CHN2 | not stated | 52 | safety | 2012 | not stated | not stated | not stated | not stated | not stated | open_label | industry | age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 11.0 percent on metformin and/or sulfonylurea |
| NCT05486065 | not stated | 40 | full_analysis | 2022 | not stated | not stated | not stated | not stated | not stated | double_blind | industry | age 18 to 64; HbA1c 7.0 to 10.5; BMI 27 or more; on metformin |
| SUSTAIN 8 | not stated | 52 | full_analysis | 2017 | not stated | not stated | not stated | not stated | not stated | double_blind | industry | age 18 or older; HbA1c 7.0 to 10.5 percent; eGFR 60 or higher; metformin 1500 mg or maximum tolerated |
| SUSTAIN™ 2 | not stated | 56 | full_analysis | 2013 | not stated | not stated | not stated | not stated | not stated | double_blind | industry | type 2 diabetes on metformin and or thiazolidinedione; HbA1c 7.0 to 10.5 percent |
| DUAL™ I Japan | not stated | 52 | full_analysis | 2015 | not stated | not stated | not stated | not stated | not stated | open_label | industry | Japanese adults 20 or older; HbA1c 7.0 to 11.0 percent; BMI at least 20; insulin naive on one oral drug |
| NCT00700817 | not stated | 52 | other | 2008 | not stated | not stated | not stated | not stated | not stated | open_label | industry | age 18 to 80; HbA1c 7.5 to 10%; BMI 45 or less; metformin 1500 mg/day or more for 3 months |
| S002969 | not stated | 52.14 | modified_itt | 2018 | not stated | not stated | not stated | not stated | not stated | double_blind | industry | age 18 to 70; BMI 30 to 50; HbA1c 48 to below 97 mmol/mol; T2DM under 10 years; undergoing LAGB |
| S003432 | not stated | 52 | other | 2020 | not stated | not stated | not stated | not stated | not stated | open_label | non_industry | age 18 to 65; type 2 diabetes 1 year or more; HbA1c 7.0 to 10.5 percent; BMI 30 or higher; stable metformin |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the mean difference on the analysis scale against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| NCT00754988 | A2 | TASP_SC_10MG_QW | 52 | arm, change | -1.600 | 0.300 | 182 | R0022521:Results | |
| NCT00754988 | A3 | TASP_SC_20MG_QW | 52 | arm, change | -2.400 | 0.300 | 187 | R0022521:Results | |
| NCT00754988 | A4 | SITAGLIPTIN | 52 | arm, change | -0.500 | 0.300 | 177 | R0022521:Results | |
| COMBINE 2 | A1 | ICOSEMA_SC_TIT_QW | 52 | arm, change | 0.890 | 0.242 | 325 | registry:outcomes | |
| COMBINE 2 | A2 | SEMA_SC_1p0MG_QW | 52 | arm, change | -3.770 | 0.251 | 336 | registry:outcomes | |
| NCT03235050 | A1 | PLACEBO | 54 | arm, change | -0.940 | 0.513 | 112 | registry:outcomes | |
| NCT03235050 | A2 | LIRA_SC_1p8MG_QD | 54 | arm, change | -2.940 | 0.520 | 110 | registry:outcomes | |
| NCT03235050 | A3 | COTA_SC_100UG_QD | 54 | arm, change | -3.200 | 0.551 | 100 | registry:outcomes | |
| NCT03235050 | A4 | COTA_SC_200UG_QD | 54 | arm, change | -3.090 | 0.344 | 256 | registry:outcomes | |
| NCT03235050 | A5 | COTA_SC_300UG_QD | 54 | arm, change | -4.350 | 0.344 | 256 | registry:outcomes | |
| SUSTAIN 7 | A1 | SEMA_SC_0p5MG_QW | 40 | arm, change | -4.560 | 0.280 | 301 | registry:outcomes | |
| SUSTAIN 7 | A2 | SEMA_SC_1p0MG_QW | 40 | arm, change | -6.530 | 0.280 | 300 | registry:outcomes | |
| SUSTAIN 7 | A3 | DULA_SC_0p75MG_QW | 40 | arm, change | -2.300 | 0.270 | 299 | registry:outcomes | |
| SUSTAIN 7 | A4 | DULA_SC_1p5MG_QW | 40 | arm, change | -2.980 | 0.270 | 298 | registry:outcomes | |
| NCT03878706 | A1 | OTHER_ACTIVE_basal_insulin | 52.14 | arm, final | 83.500 | 1.423 | 40 | R0008057:Table 2 | |
| NCT03878706 | A2 | LIRA_SC_1p8MG_QD | 52.14 | arm, final | 81.300 | 1.897 | 40 | R0008057:Table 2 | |
| NCT03878706 | A3 | EMPAGLIFLOZIN | 52.14 | arm, final | 80.600 | 1.581 | 40 | R0008057:Table 2 | |
| NCT03878706 | A4 | EMPALIRA_SC_1p8-25MG_QD | 52.14 | arm, final | 81.700 | 1.423 | 40 | R0008057:Table 2 | |
| NCT00395746 | A1 | LIRA_SC_0p6MG_QD | 52 | arm, final | 65.960 | 0.260 | 87 | registry:outcomes | |
| NCT00395746 | A2 | LIRA_SC_0p9MG_QD | 52 | arm, final | 65.870 | 0.270 | 87 | registry:outcomes | |
| NCT00395746 | A3 | PLACEBO | 52 | arm, final | 64.830 | 0.260 | 88 | registry:outcomes | |
| PIONEER 7 | A3 | SEMA_PO_FLEX_QD | 52 | arm, change | -2.600 | 0.394 | 93 | registry:outcomes | |
| PIONEER 7 | A4 | SITAGLIPTIN | 52 | arm, change | -0.900 | 0.548 | 97 | registry:outcomes | |
| SURPASS-4 | A1 | TIRZ_SC_5MG_QW | 52 | arm, change | -7.100 | 0.340 | 285 | registry:outcomes | |
| SURPASS-4 | A2 | TIRZ_SC_10MG_QW | 52 | arm, change | -9.500 | 0.340 | 288 | registry:outcomes | |
| SURPASS-4 | A3 | TIRZ_SC_15MG_QW | 52 | arm, change | -11.700 | 0.330 | 291 | registry:outcomes | |
| SURPASS-4 | A4 | INS_GLARGINE | 52 | arm, change | 1.900 | 0.190 | 891 | registry:outcomes | |
| NCT03861039 | A1 | TIRZ_SC_5MG_QW | 52 | arm, change | -3.800 | 0.510 | 148 | registry:outcomes | |
| NCT03861039 | A2 | TIRZ_SC_10MG_QW | 52 | arm, change | -7.500 | 0.510 | 146 | registry:outcomes | |
| NCT03861039 | A3 | TIRZ_SC_15MG_QW | 52 | arm, change | -10.200 | 0.520 | 145 | registry:outcomes | |
| AWARD-CHN2 | A1 | DULA_SC_1p5MG_QW | 52 | arm, change | -1.080 | 0.201 | 258 | registry:outcomes | |
| AWARD-CHN2 | A2 | DULA_SC_0p75MG_QW | 52 | arm, change | -0.760 | 0.202 | 257 | registry:outcomes | |
| AWARD-CHN2 | A3 | INS_GLARGINE | 52 | arm, change | 1.350 | 0.201 | 253 | registry:outcomes | |
| NCT05486065 | A1 | SEMA_SC_2p0MG_QW | 40 | arm, change | -8.900 | 1.136 | 56 | registry:outcomes | |
| NCT05486065 | A2 | SEMA_SC_8MG_QW | 40 | arm, change | -10.100 | 0.989 | 56 | registry:outcomes | |
| NCT05486065 | A3 | SEMA_SC_16MG_QW | 40 | arm, change | -13.100 | 1.133 | 55 | registry:outcomes | |
| NCT05486065 | A4 | PLACEBO | 40 | arm, change | -2.300 | 0.673 | 53 | registry:outcomes | |
| SUSTAIN 8 | A1 | SEMA_SC_1p0MG_QW | 52 | arm, change | -5.700 | 0.272 | 394 | registry:outcomes | |
| SUSTAIN 8 | A2 | CANAGLIFLOZIN | 52 | arm, change | -4.300 | 0.202 | 394 | registry:outcomes | |
| SUSTAIN™ 2 | A1 | SEMA_SC_0p5MG_QW | 56 | arm, change | -4.280 | 0.250 | 409 | registry:outcomes | |
| SUSTAIN™ 2 | A2 | SEMA_SC_1p0MG_QW | 56 | arm, change | -6.130 | 0.250 | 409 | registry:outcomes | |
| SUSTAIN™ 2 | A3 | SITAGLIPTIN | 56 | arm, change | -1.930 | 0.260 | 407 | registry:outcomes | |
| DUAL™ I Japan | A1 | IDEGLIRA_SC_TIT_QD | 52 | arm, change | 2.900 | 0.193 | 275 | registry:outcomes | |
| DUAL™ I Japan | A2 | INS_DEGLUDEC | 52 | arm, change | 4.100 | 0.261 | 271 | registry:outcomes | |
| DUAL™ I Japan | A3 | LIRA_SC_1p8MG_QD | 52 | arm, change | -1.000 | 0.206 | 273 | registry:outcomes | |
| NCT00700817 | A1 | LIRA_SC_1p2MG_QD | 52 | arm, change | -2.780 | 0.311 | 215 | R0024199:Results | |
| NCT00700817 | A2 | LIRA_SC_1p8MG_QD | 52 | arm, change | -3.680 | 0.311 | 214 | R0024199:Results | |
| NCT00700817 | A3 | SITAGLIPTIN | 52 | arm, change | -1.160 | 0.311 | 215 | R0024199:Results | |
| S002969 | A1 | LIRA_SC_1p8MG_QD | 52.14 | arm, change | -0.833 | 2.823 | 12 | median_converted | R0010852:Table 2 |
| S002969 | A2 | PLACEBO | 52.14 | arm, change | -6.500 | 2.958 | 13 | median_converted | R0010852:Table 2 |
| S003432 | A1 | SEMA_SC_1p0MG_QW | 52 | contrast, md | -3.500 | 0.699 | R0053844:p4 | ||
| S003432 | A2 | LIRA_SC_1p8MG_QD | 52 | contrast, md | R0053844:p4 |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.